Recent developments for Fortress Biotech include the closing of a $205 million sale of a Rare Pediatric Disease Priority Review Voucher by its subsidiary Cyprium Therapeutics, FDA approval of ZYCUBO for Menkes disease, and ongoing financial and operational updates reported in earnings releases.

• Cyprium Therapeutics closed the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million, with proceeds partially payable to a U.S. government institute [N1].
• Fortress Biotech's subsidiary Cyprium announced the FDA approval of ZYCUBO, the first and only approved treatment for Menkes disease in the United States [N8].
• The company reported earnings and operational updates in the after-hours earnings report for March 25, 2026 [N2].
• Fortress Biotech's Cyprium planned and completed the sale of a Priority Review Voucher valued at $205 million, with prior reports indicating a potential $250 million valuation [N3][N4].

Fortress Biotech benefits from a diversified portfolio of subsidiaries advancing innovative therapies, including FDA-approved products such as ZYCUBO for Menkes disease. The successful sale of a Rare Pediatric Disease Priority Review Voucher by Cyprium Therapeutics for $205 million demonstrates the company's ability to monetize valuable regulatory assets. The company's liquidity position and access to capital through equity and debt markets support ongoing development and commercialization activities. Strategic partnerships with industry leaders and a broad pipeline of product candidates across multiple therapeutic areas provide multiple avenues for growth and value creation.

Fortress Biotech faces risks related to the need for additional financing to support ongoing operations and development activities, as it has historically incurred losses and negative cash flows from operations. The company is subject to financial covenants under its credit agreements, with potential default risks if minimum liquidity and net sales thresholds are not met. Regulatory and clinical development risks inherent in biopharmaceutical product development may delay or prevent product approvals. The company's reliance on subsidiaries and partner companies for revenue generation and operational success introduces execution risks. Market competition and reimbursement challenges may also impact commercial performance.

Fortress Biotech's moat is derived from its diversified portfolio of subsidiaries and partner companies, each focused on specialized biopharmaceutical products and therapies, including rare diseases and dermatology. The company's expertise in navigating regulatory, scientific, legal, and financial complexities provides a platform to accelerate development and commercialization efforts. Strategic partnerships with established industry players and the ability to leverage priority review vouchers and milestone payments contribute to its competitive positioning. However, the biopharmaceutical industry is characterized by high development risk, regulatory scrutiny, and competitive pressures, which may impact the sustainability of Fortress's advantages.

• Financing and Liquidity Risk: The company requires additional funding through equity, debt, asset sales, or partnerships to support development and commercialization. Failure to secure adequate financing on acceptable terms could curtail development plans and operations.
• Credit Agreement Covenants: Fortress is subject to financial covenants under its senior secured credit agreement with Oaktree, including minimum liquidity and net sales requirements. Non-compliance could trigger default and acceleration of debt repayment.
• Regulatory and Development Risk: The biopharmaceutical industry involves significant regulatory hurdles and clinical development uncertainties that may delay or prevent product approvals, impacting revenue and growth.
• Dependence on Subsidiaries and Partners: The company's business model relies on the successful execution and commercialization efforts of its subsidiaries and partner companies, which introduces operational and execution risks.
• Market and Competitive Risks: Competition from other biopharmaceutical companies and challenges in reimbursement and market acceptance may affect the commercial success of Fortress's products.

• Fortress Biotech, Inc. operates through multiple subsidiaries and partner companies focused on biopharmaceutical product development and commercialization, including Journey Medical Corporation, Mustang Bio, Avenue Therapeutics, Cellvation, Cyprium Therapeutics, Helocyte, Oncogenuity, and Urica Therapeutics.
• The company leverages its expertise in business, scientific, regulatory, legal, and finance to support its subsidiaries and partners in achieving development and commercialization goals.
• Fortress Biotech's partner companies include publicly traded entities and private subsidiaries, with some having strategic partnerships with industry leaders such as AstraZeneca, Sentynl Therapeutics, Axsome Therapeutics, and Sun Pharma.
• The company reported total net revenue of approximately $63.3 million for the year ended December 31, 2025, primarily from Journey's dermatology product sales.
• Net income attributable to Fortress Biotech was $6.8 million for the year ended December 31, 2025, with a net loss per common share of $0.07.
• As of December 31, 2025, Fortress Biotech had cash and cash equivalents of approximately $79.4 million and a current ratio of 2.49, indicating liquidity sufficient to fund operations for at least 12 months following the 10-K filing date.
• The company has a $50 million senior secured credit agreement with Oaktree, amended to extend maturity to June 30, 2028, with interest-only payments and financial covenants including minimum liquidity and net sales thresholds.
• Cyprium Therapeutics, a Fortress partner, sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million, with proceeds partially payable to a U.S. government institute.
• Fortress Biotech announced FDA approval of ZYCUBO (copper histidinate), the first and only approved treatment for Menkes disease in the United States, through its subsidiary Cyprium Therapeutics.
• Checkpoint Therapeutics, previously a partner company, was sold to Sun Pharma in May 2025, generating $28 million in cash proceeds for Fortress.
• The company has ongoing research and development expenses primarily related to personnel, third-party services, and regulatory filings, expensed as incurred.
• Fortress Biotech's subsidiaries and partner companies have entered into various license agreements with upfront and milestone payments, including sales-based milestones totaling approximately $117.4 million.
• The company has experienced net losses historically but reported a positive net income attributable to Fortress in 2025, reflecting operational improvements and asset sales.
• Fortress Biotech's business model includes raising capital through equity and debt offerings, warrant exercises, and asset sales to fund operations and development activities.
• The company maintains contractual arrangements with specialty pharmacies and commercial payers, including rebates and product return policies consistent with industry practice.
• Fortress Biotech's consolidated assets totaled approximately $185.5 million as of December 31, 2025, with total liabilities of about $123.4 million and stockholders' equity of $62.2 million.
• The company has a shelf registration statement effective for issuing securities but currently is not eligible to use Form S-3 due to dividend payment status on Series A Preferred Stock, with plans to regain eligibility upon filing the annual report and meeting dividend conditions.